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Abstract
Background. Meropenem is a relatively new carbapenem in some Middle East 
countries; our aim is to evaluate its susceptibility in gram-negative pathogens isolat-
ed from ICU patients and to identify the prevalence of ICU bacterial isolates identified 
as pathogens based on CDC-NHSN definition for pathogens in the affected organs.
Methods. Pathogens as identified by CDC-NHNS were studied for prevalence and 
antibiotic susceptibility. Patients and charts were prospectively reviewed; attending 
physician diagnosis was considered after being reviewed by two qualified infection 
control nurses and infectious diseases physician. 
Results. One-hundred and seventy-three gram-negative pathogen were reviewed 
for susceptibilities and ESBL production. E. coli was a dominant pathogen followed 
by Klebsiella, and Pseudomonas. ESBL-production was in E. coli (62.7%) and Klebsi-
ella (58.6%), considering all gram-negative bacilli studied; ESBL rates were 30.7%. 
Both Carbapenems showed superior activity against gram-negative pathogens. Me-
ropenem did better than imipenem against pseudomonas species, but PIP/TAZ did 
better than both carbapenems (p = 0.02). The difference in susceptibility patterns 
among ESBL-producing pathogens compared with same non-ESBL producers spe-
cies showed that carbapenems were superior to other classes of antibacterials tested 
in this regard, and rates of resistant ESBL to both carbapenems were 5.6%; trustwor-
thy in the initial empiric therapy in ICUs and hospitals that suffer from high rates of 
ESBL-producers. While PIP/TAZ showed highly significant difference (p < 0.0001) in 
activity against ESBL and non-ESBL producers.
Conclusion. Meropenem and imipenem are trustworthy in the initial empiric 
therapy. Gram-negative pathogens are highly susceptibility to both carbapenems, 
and benefit extends to ICUs with high rates of ESBL-producers.
Keywords: Meropenem, Imipenem, “Gram-negative pathogens ‘susceptibility”, 
ESBL-producer, ICU-Jordan
Introduction
Intensive care units’ beds occupy about 10% of hospital beds 
meanwhile representing the hospital epidemiology in as much 
as 80%, where most of infections take place in ICU. (1, 2) Fur-
thermore, the amount of antibacterial drugs used is enormous 
in this part of the hospital, especially wide-spectrum antibac-
terials as mono-therapy or in combination. Among antibacteri-
als, carbapenems are widely used, and meropenem is a rela-
tively new antimicrobial agent in our part of the world. Some 
studies state that it is different from imipenem in its potency 
and target attainment, especially against Pseudomonas spe-
cies.(3) The major concern of infectious disease has been in 
the last decades the problem of combating resistance. Many 
antimicrobial agents became less useful as resistance evolve.
(4) Resistance trends among bacteria are on the rise in hospi-
tals, especially in ICUs where highly morbid patients are resid-
ing, with multiple interventions, and the use of wide-spectrum 
antimicrobials, among other risk factors.(5, 6) Gram-negative 
bacteria contribute to a large fraction of ICU nosocomial infec-
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tions, mostly contributing to a big part of ventilator-associated 
pneumonia (VAP), catheter-associated urinary tract infections 
(CAUTI) and central line associated infections (CLABSI) as iden-
tified by CDC-NHNS.(4, 7) Vigilance is highly needed in this 
regard and adjusting antimicrobials use in ICUs has to cope 
with the evolving changes in prevalence and susceptibility. 
The invaluable continued ICU surveillance for prevalence of 
pathogens and their antimicrobial susceptibility shed light on 
empiric treatment; here, using meropenem as a model to com-
pare with.(7) The ultimate goal is that antimicrobial prescrip-
tion would be more educated, based on proper  suspicion of 





The study was conducted in Amman-Jordan in  two private 
hospitals with a total bed  occupancy of 370 and total ICU 
beds of 45 (The Specialty Hospital and Al Khalidi Hospital). The 
study period was from September 2009 – February 2011. Iso-
lates were processed for susceptibility by Viteck II ( BioMérieux 
SA. F-69280 Marcy l’Etoile, France) few isolates were processed 
by E-test (AB BIODISK Dalvägen 10, S - 169 56 Solna, Sweden). 
Antimicrobials used for susceptibilities including meropenem, 
imipenem, ertapenem, PIP/TAZ, tigecycline, cefepime, ceftazi-
dime, ceftriaxone,, ciprofloxacin, levofloxacin and aztreonam. 
Gram-negative pathogens tested were those isolated from all 
sources (table 1);  Escherichia coli, Klebsiella pneumonia, Pseudo-
monas aeruginosa, Pseudomonas species,  Acinetobacter com-
plex, Enterobacter spp. Serratia marscesenece and others bacte-
ria spp. like  (Proteus mirabilis, Morganella morgani, Providentia 
stuarti, Chrysomonas luteola, Flavimonoas arrhyzohabitans). 
 Definitions and Methodology
 Four major indicators are utilized in both hospitals (quality 
performance indicators) were considered for obtaining isolates 
(VAP, CLABSI, CAUTI and SSI), an isolate is considered a patho-
gen and included in the study when causing infection in the 
organ as it followed the definition for hospital-acquired infec-
tions described by CDC-NHSN. (7) Qualified infection control 
nurses (M.A and A.S) collect cultures results from the microbi-
ology laboratory. The methodologies of pathogens’ sampling 
were monitored, especially in VAP, whether samples were taken 
from tracheal aspiration or BAL or other methods, abiding by 
CDC-NHSN definition. Daily collected cultures were discussed 
on case-by-case basis, with patients’ chart review, radiological 
review, urine analysis and blood cultures with an infectious dis-
eases physician, before enrolling the suspect pathogen in the 
study. In the other hospital, a qualified experienced infection 
control nurse did the review and strictly applied same CDC-
NHNS definitions, keeping in contact with the same infectious 
diseases physician (J.W).
 Microbiological Methodology
Microbiological procedures to identify the target microorgan-
isms: specimens from the target sources are cultured on blood-
agar, chocolate-agar, MacConkey’s agar & SAB agar plates Pus 
was cultured on two plates of blood agar (aerobic and anaero-
bic incubation) and on chocolate agar, MacConkey’s agar & SAB 
agar plates. Pus is also  incubated in thioglycolate for growth 
augmentation, subsequently cultured on plates as above  in 
twenty-four, forty-eight hours and at the end of incubation i.e. 
five days. Chocolate agar plates were incubated in CO2 environ-
ment  for twenty-four hours. Microorganisms were identified 
from growth plate by colony morphology (shape, color, size) 
and gram stain; Gram-negative bacteria grew on selective Mac-
 TABLE 1. Gram-negative Pathogens isolated in ICU Setting, and their Distribution according to Source.
Pathogens CLABSI CAUTI VAP SSI Total No. of Pathogens
E.coli 17 32  0 7 56
K. pneumonia 9 14 4 2 29
P. aeruginosa  7 10 4 5 26
Acinetobacter spp. 9 7 8 4 28
Enterobacter spp. 2 2  0 2 6
Pseudomonas spp.  6  0  0 0 6
Other GNB 7 6 0 9 22
Total 57 71 16 29 173
CLA-BSI:  Central line associated blood stream infection. CA-UTI: Catheter associated urinary tract infection. VAP: ventilator associated pneumonia. SSI: Surgical 
site infection.
 Others GNB:  Serratia marscesence, Flavimonas arryzohabitanz, Hemophilus influenzae, Proteus mirabilis, Morganella spp., Providentia spp., Chrysomonas luteola, 
Achromobacter sppecies.
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Conkey’s agar plate, and then identified as lactose fermenter 
(LF) or non-fermenter (NLF) and processed by the automated 
Viteck II. Microorganism susceptibility is processed by isolating 
colonies in one of sterile solutions (saline solution for use in 
Viteck II); suspension density is checked by the digital density 
check (0.5-0.63) densitocheck(add the name of company and 
country). The results are reported as minimum inhibitory con-
centration (MIC) according to the published document by clini-
cal and laboratory standards institute (CLSI) break points( 8).  E.
coli ATCC 25922 and P. aeruginosa ATCC 25423 were used as 
Controls.
 Statistical analysis
All results were uploaded into statistical software (SPSS ver-
sion 15). Data generation for tables, numbers, ratios as well as 
raters were measured. Where appropriate, the differences in 
susceptibility among gram-negative pathogens were calcu-
lated using 95% confidence intervals and P-value (p-value to 
be < 0.05). The hypothesis was that meropenem is different 
from other antimicrobials especially imipenem, in its activity 
against major ICU gram-negative pathogens. Susceptibility of 
pseudomonas to meropenem and imipenem were specifically 
measured for the claim that meropenem is more of anti-pseu-
domonal than imipenem. Furthermore, p-value was calculated 
based on meropenem as a reference for other selected anti-
pseudomonal antimicrobials, representing different antimicro-
























































 FIGURE 1.   Susceptibility of Pseudo-
monas aeruginosa includ-
ing Pseudomonas species 
to selected antimicrobial 
agents expressed in per-
centages.
Numbers below antimicrobials denote the total pathogens susceptible over total tested for that 
antimicrobial. P-values are for comparing meropenem with the respected antimicrobial. Z: the 
























 Two-hundred twenty pathogen were isolated; 39 gram-posi-
tive, 173 gram-negative (54 ESBL; 30.7%), and 8 Candida spe-
cies. Eight were duplicate isolates considered all as pathogens; 
it was not certain which one was the pathogen in the absence 
of lung biopsy for gram staining, to correlate with culture 
(however, 6 Candida were isolated with gram-negative bacilli, 
and 2 S. fecalis with gram negative-bacilli), gram-negative ba-
cilli were considered the pathogens for they were treated by 
the attending physician.
One-hundred seventy-three gram-negative pathogens (table 
1) were isolated from CLABSI, CAUTI, VAP and SSI. E. coli was 
dominant (N = 56) pathogen, mostly was isolated from urinary 
source (n = 32) followed by CLABSI (n = 17). K. pneumonia (N 
= 29) was isolated from CATUI (n = 14), followed by CLABSI (n 
= 9) and VAP (n = 4). P. aeruginosa (N = 26) from CAUTI (n= 
10), from CLABSI (n = 7), and from VAP (n = 4) and SSI (n = 5) 
pathogens. Acinetobacter species were more-or-less uniformly 
isolated from all sources (N = 28). Enterobacter species and 
Pseudomonas species were minor in numbers; the “other gram-
negatives” were heterogenous and came from SSI, CLABSI and 
CAUTI.
Carbapenems (meropenem, imipenem and ertapenem) 
showed superior activity over other tested antimicrobial class-
es against E. coli, K. pneumonia and Enterobacter spp. (Table 2), 
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but within the same class; meropenem did better than imi-
penem against pseudomonas species, However both carbap-
enems have 5.6% resistance rates among the fifty-four tested 
ESBL producing gram-negative bacilli. PIP/TAZ did better than 
both carbapenems (p = 0.02) against Pseudomonas aeruginosa 
and species (Figure 1). Lumping gram-negative pathogens 
susceptibility together, as what actually occur in “clinical ini-
tial empiric therapy”; carbapenems, tigecycline, and amika-
cin were better in activity than other tested antimicrobials 
(Table 3 and Figure 2).
ESBL was detected by Viteck II employing Ceftazidime, cef-
triaxone and aztreonam plus clavulonic acid (in combination 
with amoxicillin), subtypes were CTX-M 31%, SHV 10.3%, AmpC 
19%, others 5.2% and untypable 34.5%. ESBL’s distribution 
among each gram-negative were; E. coli (62.7%), K. pneumonia 
(58.6%) and Enterobacter (100%). ESBL rates were 30.7% of all 
gram-negatives, and 44.5% of ESBL-producing gram-negative 
pathogens.
























E. col n=56 49 / 1 54 / 1 54 / 1 29 / 24 11 / 4 18 / 38 17 / 33 50 / 1 19 / 13 18 /12 13 / 13
K.pneumoniae  
n= 29
27 / 2 27 / 2 28 / 1 17 / 11 8 / 3 12 / 15 12 / 13 24 / 1 13 / 4 11 / 6 10 / 3
P. aeruginosa 
 n = 26
13 / 10 14 / 12 21 / 5 18 / 7 0 / 3 15 / 11 12 / 9 0 / 1 0 / 6 18 / 8 10 / 11
Acinetobacter   
n = 28
2 / 26 2 / 26 10 / 17 2 / 26 14 / 8 1 / 24 1 / 21 0 / 11 1 / 19 2 / 23 1 / 20
Enterobacter   
n = 6
6 / 0 6 / 0 4 / 1 4 / 1 1 / 0 3 / 2 3 / 4 2 / 1 3 / 2 3 / 1 2 / 1
Pseudomonas 
spp. n = 7
4 / 2 0 / 7 1 / 6 7 / 0 0 / 1 2 / 5 2 / 1 -------- 0 / 4 4 / 3 3 / 3
PIP/TAZ: pipracillin-tazobactam. 
S; Susceptible, R: resistant, n: total number of pathogens tested to various antimicrobials. 
TABLE 3. Antimicrobial susceptibility of all Gram-negative bacilli isolated from all sources
Antibiotics Susceptible Intermediate Resistant % Susceptible
The Percent difference of each 
antimicrobial vs. Meropenem 
and (95% C.I.)
Meropenem 125 5 54 67.4 ---
Imipenem 134 5 68 64.7 -2.7  (-6 to 12)
PIP/TAZ 106 4 85 54.4 -13   (-3 to -23)
Ertapenem 86 1 15 84.3 16.9  (7- 27)
Levofloxacin 69 5 99 39.9 -27.5 (-17 to -37)
Ciprofloxacin 71 3 127 35.3 -32.1 (-22 to -41)
Ceftriaxone 45 1 64 40.9 -26.5 (-15 to - 38)
Amikacin 135 2 35 78.5 11.1  (2 - 20)
Tigecycline 70 6 18 74.5 7.1   (-4 to 18)
Cefepime 66 5 52 53.6 -13.8 (-3 to -25)
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 FIGURE 2.   Forest representation of the 95% confidence interval comparing meropenem activity against Gram-negative pathogens 
with other antimicrobials (data from table 3).
Discussion
In our current study as well as in others, Enterobacteriaceae 
dominated the isolates, thus, being frequent candidate patho-
gens causing sepsis in ICUs. (8) E. coli was the prevalent patho-
gen 56 (32.4%), followed by K. pneumonia, Pseudomonas aeru-
ginosa and Acinetobacter species. This is divergent from some 
prevalence studies of isolates where it showed dominance 
of Pseudomonas aeruginosa in a US study.(9) While in Europe 
Enterobacteriaceae lead by E. coli was dominant.(8) However 
both studies show that Acinetobacter and Serratia marscesence 
defined as pathogens are less than what physicians use to di-
agnose and treat in ICUs.(8, 9)
Meropenem is a carbapenem belongs to the same family of 
antimicrobials with imipenem and ertapenem as well as oth-
ers not yet available in our part of the world e.g. Doripenem, 
Faropenem, Panipenem, and the investigational agents; Tomo-
penem, Tebinepem, Razupenem.(10) Meropenem mechanism 
of action against pseudomonas is exerted through binding to 
PBP2 and PBP3, while in E. coli it binds to PBP2, much similar 
to the recently released doripenem, while imipenem binds to 
PBP1a and PBP1b in Pseudomonas.(11) This may reflect on me-
ropenem in being a marginally better anti-pseudomonal and 
antigram-negative agent.(12)
In our study meropenem showed tendency towards being 
better anti-pseudomonal than imipenem (p = 0.07), while it 
showed no significant difference against the other tested 
gram-negative pathogens (p > 0.05). PIP/TAZ showed a sig-
nificant but marginal better anti-pseudomonal activity than 
meropenem, p = 0.02 (Fig 1). Both carbapenems harbor 5.6% 
resistance rates among the fifty-four tested ESBL producing 
gram-negative bacilli.
However, considering all gram-negative pathogens together 
for susceptibility, as actually what happens in the clinical ap-
proach for initial empiric therapy, Imipenem is the only anti-
microbial that is comparable with meropenem. While other 
antimicrobials like Amikacin (95% C.I, 0.02 - 0.27), ertapenem 
(95% C.I, 0.07-0.27) show tendency towards a better suscep-
PIP/TAZ: pipracillin-tazobactam
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TABLE 4.  Gram-negative bacilli showing ESBL production and ESBL-producers distribution according to their source.
Gram-negative pathogens 
Source
CLA-BSI CA-UTI VAP SSI Total (%)






















































Total ESBL-Producing bacteria and rates per source 14 (50%) 33 (68.7%) 2 (50%) 11 100%
Total ESBL rates from E.coli, K. pneumonia and Enterobacter spp. from all sources were = 44.5%. Total ESBL rates from all gram-negative pathogens isolated from 
all sources were 30.7%. CLA-BSI: Central line associated blood stream infection. CA-UTI: Catheter associated urinary tract infection. VAP: ventilator associated 
pneumonia. SSI: Surgical site infection.
ESBL-GNB: Extended spectrum beta lactamase- producing gram-negative bacilli.
TABLE 6. Susceptibility of ESBL-producing and-nonproducing Gram-negative bacilli to meropenem and to other tested comparator antimicrobials 
Susceptible
ESBL 
Yes       No
Intermediate
ESBL        
Yes         No
Resistant
ESBL        
Yes         No
(%) Susceptible
ESBL
Yes         No
Difference in percent 
Susceptibility and
(95% C.I)
Meropenem 46            27 0                   0 3                 1 94                96 4       (-8 - 12)
Imipenem 50            28 0                   0 3                 3 94                90 4       (-8 - 16)
PIP/TAZ 18            25 2                   0 30               3 36                89 -53  ( -35 to- 70)*
Tigecycline 13             8 0                   0 4                 3 76                73 3       (-30 - 36)
Ertapenem 46            25 0                   0 2                 0 96                93 3       (-8 - 14)
Levofloxacin 7             20 2                   0 37               7 15                74 -59   (-39 to -78)*
Ciprofloxacin 7             23 1                   0 44               7 14                77 63  (-45 to -81) *
Ceftriaxone 3             26 0                   0 16               2 16                93 77  (-58 to -96) *
Amikacin 51            28 1                   0 1                 0 98              100 -2      (-2 - 6)
Aztreonam 0             19 0                   0 16                1 00                95 -95 (-85 to -100)*
*  Starred antimicrobials show significant difference in activity against ESBL and non-ESBL producing gram-negative bacilli. 
ESBL-GNB: Extended spectrum beta lactamase- producing gram-negative bacilli.
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tibility patterns in vitro, and tigecycline show no significant 
difference (95% C.I, -0.04 to 0.18) in susceptibility patterns in 
comparison with meropenem. Nevertheless, the later three 
agents are not approved and should not be used in sever sep-
sis syndrome or bacteremia.(13, 14, 15, 16) Moreover, PIP/TAZ 
showed tendency towards less activity than meropenem when 
gram-negative pathogens were considered together (95%C.I, 
-0.023 to – 0.030).
ESBL- producers were found among E. coli, K. pneumonia, and 
Enterobacter species. The prevalence of ESBL-producers was 
30.7% of all gram-negative pathogens, and 44.5% among the 
aforementioned ESBL-producers. E. coli lead the three patho-
gens in ESBL production (Table 4) contrary to other previous 
studies that showed K. pneumonia was the leader.(17) The dif-
ference in susceptibility among ESBL-producing pathogens 
compared with same non-ESBL producers show that merope-
nem (difference = 4, 95% C.I -8 to 12) and imipenem (differ-
ence = 4, 95% C.I -8 to 16) are again trust worthy in the initial 
empiric therapy in ICUs and hospitals that suffer from high 
rates of ESBL-producers, and both were comparable. PIP/TAZ, 
an agent that is frequently used in ICU for sever sepsis of dif-
ferent sources, showed highly significant difference in activity 
against ESBL-producers and non-producers (difference = -53, 
95% C.I, -35 to -70, p < 0.0001). The finding in these pathogens 
point that IDSA recommendations in using PIP/TAZ in ESBL-
producers in complicated intra-abdominal infections is to be 
employed in community-acquired infections or health care-
associate intra-abdominal infections if their total rates of ESBL 
are less than 20%, or ESBL-subtypes are known, e.g. SHV and 
Toho-2 were not prevalent. (17, 18) ESBL sub-typing is not avail-
able in a good number of laboratories.
This study utilizing pathogens showed that meropenem and 
imipenem are trustworthy in the initial empiric therapy be-
fore the the documented pathogen is known, since the rates 
of gram-negative pathogens’ susceptibilities are the highest 
among tested agents potentially used in ICU sepsis. Looking 
for antimicrobials’ susceptibility among pathogens is not com-
mon in literature for being tedious, though this approach may 
be more accurate in clinical management of patients, especially 
bacteria of the same species may be different in genotypes or 
serotypes, which translate to pathogenesis potentials.(19, 20) 
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